Search

Corvus Pharmaceuticals Inc

Открыт

13.93 -0.29

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

13.76

Макс.

14.25

Ключевые показатели

By Trading Economics

Доход

-1.4M

-14M

Прибыль на акцию

-0.15

Сотрудники

37

EBITDA

312K

-12M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+127.01% upside

Дивиденды

By Acuity

Следующий отчет о доходах

6 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-223M

1.1B

Предыдущая цена открытия

14.22

Предыдущая цена закрытия

13.93

Corvus Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 23:56 UTC

Baidu Inc. shares are roughly flat in after-market trading, remaining near unchanged since Tuesday's close and positioned around the midpoint of its one-month range.

4 авг. 2026 г., 23:56 UTC

Ziff Davis Inc shares are lower during after-market hours, with no specific news identified to explain the movement. The stock fluctuated earlier in the session.

4 авг. 2026 г., 23:56 UTC

Centene Corp shares are higher in after-market hours, continuing a recent upward trend amid positive market sentiment following a narrowing U.S. trade deficit.

4 авг. 2026 г., 23:56 UTC

Insulet Corp shares are lower in after-market hours, showing little change since Tuesday's close amid a lack of specific company news.

4 авг. 2026 г., 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

4 авг. 2026 г., 23:56 UTC

Xcel Energy shares advanced in after-market trading, reaching a high of 0.60% above Tuesday's close, though still below the 20-day moving average.

4 авг. 2026 г., 23:56 UTC

Nasdaq Inc. shares showed routine trading activity during after-market hours, remaining roughly flat since Tuesday's close and positioned above its 20-day moving average.

4 авг. 2026 г., 23:56 UTC

Correlated Moves
ETF Constituents
Macro News

The iShares U.S. Aerospace & Defense ETF is trading higher in after-market hours, supported by positive earnings from technology stocks and geopolitical developments.

4 авг. 2026 г., 23:56 UTC

Darling Ingredients Inc shares are higher in after-market trading, rebounding from earlier session lows. No specific news was identified to explain the movement.

4 авг. 2026 г., 23:56 UTC

ETF Constituents

The Consumer Staples Select Sector SPDR Fund traded near unchanged in after-market hours, supported by positive contributions from Walmart, Costco, and PepsiCo.

4 авг. 2026 г., 23:56 UTC

Public Service Enterprise Group Inc shares are modestly higher in after-market hours. No specific company news was identified to explain the movement.

4 авг. 2026 г., 23:56 UTC

TE Connectivity Ltd. shares are lower in after-market trading, retracing from earlier gains. The stock remains above its 20-day moving average.

4 авг. 2026 г., 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, moving lower since Tuesday's close. The stock remains above its 20-day moving average.

4 авг. 2026 г., 23:56 UTC

TAL Education Group shares are higher in after-market hours, recovering slightly after three consecutive sessions of decline and remaining above the 20-day moving average.

4 авг. 2026 г., 23:56 UTC

Packaging Corp of America shares were roughly flat in after-market hours, remaining above their 20-day moving average following three consecutive higher sessions.

4 авг. 2026 г., 23:56 UTC

Regions Financial Corp shares are higher in after-market hours, continuing a trend of strength following four consecutive sessions of gains.

4 авг. 2026 г., 23:56 UTC

Fuelcell Energy Inc shares are lower in after-market trading, with no specific company news identified to explain the decline following Tuesday's close.

4 авг. 2026 г., 23:56 UTC

MACOM Technology Solutions Holdings Inc. shares are lower in after-market trading, reflecting routine fluctuations and positioning below the 20-day moving average.

4 авг. 2026 г., 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

4 авг. 2026 г., 23:56 UTC

MKS Instruments Inc shares are lower in after-market hours, reflecting notable weakness as they remain significantly below their 20-day moving average.

4 авг. 2026 г., 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

4 авг. 2026 г., 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

4 авг. 2026 г., 23:56 UTC

The US 10Y Treasury Bond Index is trading roughly flat. The U.S. trade deficit narrowed to $73.3 billion in June from $77.6 billion in May.

4 авг. 2026 г., 23:56 UTC

Whirlpool Corp shares are trading lower in after-market hours, with no specific news identified to explain the movement. They remain near the upper end of their one-month range.

4 авг. 2026 г., 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, following a volatile session with no specific news identified to explain the movement.

4 авг. 2026 г., 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

4 авг. 2026 г., 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

4 авг. 2026 г., 23:56 UTC

Ultra Clean Holdings Inc. shares are higher in after-market trading, despite no specific company news identified. The broader market reflects a narrowing U.S. trade deficit.

4 авг. 2026 г., 23:52 UTC

Correlated Moves

Teradyne Inc. shares gained in after-market trading, reflecting positive sentiment in U.S. markets amid easing inflation concerns related to oil supply negotiations.

4 авг. 2026 г., 23:52 UTC

Brazil's upcoming inflation report on August 11, 2026, is poised to influence central bank policy amid rising energy prices and declining manufacturing activity.

Сравнение c конкурентами

Изменение цены

Corvus Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

127.01% рост

Прогноз на 12 месяцев

Средняя 31.6 USD  127.01%

Максимум 40 USD

Минимум 27 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Corvus Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat